Education
About Us
Working with TipRanks
Follow Us
RAPT Therapeutics (RAPT)
NASDAQ:RAPT
RAPT Stock Chart & Stats
$33.18
-$0.14(-8.75%)
At close: 4:00 PM EST
$33.18
-$0.14(-8.75%)
Day’s Range― - ―
52-Week Range$5.67 - $42.39
Previous CloseN/A
Volume421.15K
Average Volume (3M)388.20K
Market Cap
$943.00M
Enterprise Value$540.63M
Total Cash (Recent Filing)$157.34M
Total Debt (Recent Filing)$2.60M
Price to Earnings (P/E)―
Beta1.60
Next Earnings
Mar 05, 2026EPS Estimate
-0.81Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.65
Shares Outstanding27,710,870
10 Day Avg. Volume380,206
30 Day Avg. Volume388,196
Financial Highlights & Ratios
PEG Ratio-0.86
Price to Book (P/B)2.71
Price to Sales (P/S)0.00
P/FCF Ratio-6.18
Enterprise Value/Market Cap0.57
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit-2.70K
Enterprise Value/Ebitda-5.01
Forecast
1Y Price Target
$64.38Price Target Upside94.03% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering9
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Clinical Trial SuccessRAPT disclosed highly encouraging topline data from the Phase 2 trial of ozureprubart in chronic spontaneous urticaria.
Financial PositionFollowing the positive results, RAPT raised $250M in gross proceeds from a stock offering, which should help operations into mid-2028, including the initiation of a Phase 3 program with ozureprubart in CSU.
Regulatory ProgressThe FDA announced that one pivotal trial could be sufficient for approval for new therapies, which could accelerate timing for ozureprubart's path to market.
Bears Say
Financial PerformanceRAPT reported a net loss of $17.6M, or $0.65/share, in Q3 2025, compared to a net loss of $18.4M, or $3.79/share, in Q3 2024.
Trial LimitationsA less impactful second readout from Jeyou in asthma is expected, which is a smaller Phase 2a study not powered for efficacy endpoints.
RAPT Therapeutics News
RAPT FAQ
What was RAPT Therapeutics’s price range in the past 12 months?
RAPT Therapeutics lowest stock price was $5.67 and its highest was $42.39 in the past 12 months.
What is RAPT Therapeutics’s market cap?
RAPT Therapeutics’s market cap is $943.00M.
When is RAPT Therapeutics’s upcoming earnings report date?
RAPT Therapeutics’s upcoming earnings report date is Mar 05, 2026 which is in 76 days.
How were RAPT Therapeutics’s earnings last quarter?
RAPT Therapeutics released its earnings results on Nov 06, 2025. The company reported -$0.65 earnings per share for the quarter, beating the consensus estimate of -$0.978 by $0.328.
Is RAPT Therapeutics overvalued?
According to Wall Street analysts RAPT Therapeutics’s price is currently Undervalued.
Does RAPT Therapeutics pay dividends?
RAPT Therapeutics does not currently pay dividends.
What is RAPT Therapeutics’s EPS estimate?
RAPT Therapeutics’s EPS estimate is -0.81.
How many shares outstanding does RAPT Therapeutics have?
RAPT Therapeutics has 27,710,870 shares outstanding.
What happened to RAPT Therapeutics’s price movement after its last earnings report?
RAPT Therapeutics reported an EPS of -$0.65 in its last earnings report, beating expectations of -$0.978. Following the earnings report the stock price went up 2.724%.
Which hedge fund is a major shareholder of RAPT Therapeutics?
Currently, no hedge funds are holding shares in RAPT
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
RAPT Therapeutics Stock Smart Score
Outperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$64.38 (94.03% Upside)
$64.38 (94.03% Upside)
Blogger Sentiment
Bullish
RAPT Sentiment 100%
Sector Average ―
Sector Average ―
Crowd Wisdom
Very Positive
Last 7 Days ▲ 7.2%
Last 30 Days ▲ 20.2%
Last 30 Days ▲ 20.2%
News Sentiment
Neutral
Bullish news 50%
Bearish news 50%
Bearish news 50%
Technicals
SMA
Positive
20 days / 200 days
Momentum
393.16%
12-Months-Change
Fundamentals
Return on Equity
-85.37%
Trailing 12-Months
Asset Growth
52.80%
Trailing 12-Months
Company Description
RAPT Therapeutics
RAPT Therapeutics, Inc., a clinical-stage immunology-based biopharmaceutical company, focuses on discovering, developing, and commercializing oral small molecule therapies for patients with unmet needs in oncology and inflammatory diseases. Its lead inflammation drug candidate is RPT193, a C-C motif chemokine receptor 4 (CCR4) antagonist that selectively inhibit the migration of type 2 T helper cells into inflamed tissues. The company's lead oncology drug candidate is FLX475, an oral small molecule CCR4 antagonist that is in the Phase 1/2 clinical trial to investigate as a monotherapy and in combination with pembrolizumab in patients with advanced cancer. It also focuses on the development of hematopoietic progenitor kinase 1 inhibitor. The company was formerly known as FLX Bio, Inc. and changed its name to RAPT Therapeutics, Inc. in May 2019. RAPT Therapeutics, Inc. was incorporated in 2015 and is headquartered in South San Francisco, California.
RAPT Stock 12 Month Forecast
Average Price Target
$64.38
▲(94.03% Upside)
Technical Analysis
Neurogene
―
DBV Technologies SA - American
―
Autolus Therapeutics
―
enGene Holdings
―
Lexeo Therapeutics, Inc.
―
Ownership Overview
7.36%
Insiders
3.24% Mutual Funds
42.32% Other Institutional Investors
43.06% Public Companies and
Individual Investors